Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;18(12):739-740.
doi: 10.1038/s41581-022-00619-3.

Electronic patient-reported outcomes in chronic kidney disease

Nicola Anderson  1 , Derek Kyte  2 , Christel McMullan  3 , Paul Cockwell  4 , Olalekan L Aiyegbusi  3 , Ravinder Verdi  5 , Melanie J Calvert  3
Affiliations

Electronic patient-reported outcomes in chronic kidney disease

Nicola Anderson et al. Nat Rev Nephrol. 2022 Dec.

Abstract

Considerable research and investment have focused on the use of electronic patient-reported outcomes (ePROs) in nephrology. However, systematic collection of ePROs to inform the care of patients with chronic kidney disease remains sporadic. A change in culture is needed to encourage their wider adoption in clinical practice.

PubMed Disclaimer

Conflict of interest statement

N.A. receives funding from the National Institute for Health and Care Research (NIHR) and personal fees from GlaxoSmithKline (GSK) outside the submitted work. M.J.C. is director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, director of the Centre for Patient Reported Outcomes Research and a NIHR senior investigator. M.J.C. receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, and NIHR Applied Research Collaboration (ARC) West Midlands, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, SPINE UK, UKRI, UCB Pharma, Janssen, GSK and Gilead. M.J.C. has received personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. D.K. reports grants from Macmillan Cancer Support, Innovate UK, the NIHR, NIHR Birmingham BRC, and NIHR SRMRC, and personal fees from Merck and GSK outside the submitted work. C.M. receives funding from the NIHR SRMRC, the NIHR Birmingham-Oxford BTRU in Precision Transplant and Cellular Therapeutics, and Innovate UK, and has received personal fees from Aparito Ltd outside the submitted work. O.L.A. receives funding from the NIHR BRC, NIHR ARC, West Midlands, NIHR Birmingham-Oxford BTRU in Precision Transplant and Cellular Therapeutics, Innovate UK, Gilead Sciences Ltd, Janssen Pharmaceuticals, Inc. and Sarcoma UK. O.L.A. declares personal fees from Gilead Sciences Ltd, GSK and Merck outside the submitted work. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

References

    1. Fletcher BR, et al. Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. PLoS Med. 2022;19:e1003954. doi: 10.1371/journal.pmed.1003954. - DOI - PMC - PubMed
    1. Schick-Makaroff K, et al. An evidence-based theory about PRO use in kidney care: a realist synthesis. Patient. 2021;15:21–38. doi: 10.1007/s40271-021-00530-2. - DOI - PubMed
    1. Basch E, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. J. Am. Med. Assoc. 2017;318:197–198. doi: 10.1001/jama.2017.7156. - DOI - PMC - PubMed
    1. Lizée T, et al. Cost-effectiveness of web-based patient-reported outcome surveillance in patients with lung cancer. J. Thorac. Oncol. 2019;14:1012–1020. doi: 10.1016/j.jtho.2019.02.005. - DOI - PubMed
    1. Schougaard LMV, et al. AmbuFlex: tele-patient-reported outcomes (telePRO) as the basis for follow-up in chronic and malignant diseases. Qual. Life Res. 2016;25:525–534. doi: 10.1007/s11136-015-1207-0. - DOI - PMC - PubMed